Read more
This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding feld. It serves as an
authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine,
cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and
cellular mechanisms involving platelets.
List of contents
Chapter 60: Approach to patients with suspected platelet-related bleeding.- Chapter 61: Inherited thrombocytopenias.- Chapter 62: Immune thrombocytopenia.- Chapter 63: Fetal and neonatal alloimmune thrombocytopenia.- Chapter 64: Drug-induced thrombocytopenia.- Chapter 65: Thrombocytopenia in pregnancy.- Chapter 66: Thrombocytopenia in cancer.- Chapter 67: Miscellaneous causes of thrombocytopenia.- Chapter 68: Inherited platelet function disorders: adhesive protein defects.- Chapter 69: Inherited platelet function disorders: G protein-coupled receptor defects.- Chapter 70: Inherited platelet function disorders: defects of content and secretion of platelet granules.- Chapter 71: Inherited platelet function disorders: signal transduction defects.- Chapter 72: Inherited platelet disorders: defects of transcription factors.- Chapter 73: Inherited platelet function disorders: defects of cytoskeletal proteins.- Chapter 74: Inherited platelet function disorders: defects of membrane phospholipids.- Chapter 75: Inherited platelet function disorders: Quebec platelet disorder.- Chapter 76: Acquired disorders of platelet function.- Chapter 77: Management of bleeding in antiplatelet-treated patients.- Chapter 78: Autoimmune platelet function disorders.
About the author
Prof. Paolo Gresele, MD, PhD, is Professor of Internal Medicine at the Department of Medicine and Surgery of the University of Perugia, Italy. His research interests are mainly focused on hemostatic and thrombotic disorders, with special attention on the role of platelets in hemorrhagic, cardiovascular and inflammatory diseases. He has been President of Italian Society on Hemostasis and Thrombosis, former chair of the Platelet Physiology Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH) he is member of the panel of experts on ClinGen Hemostasis/Thrombosis Clinical Domain Working Group and is the current Chair of the Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders of the European Hematology Association (EHA-SWG).
Dr. José A. López, MD has held academic positions at the University of California, San Francisco and Gladstone Institute for Cardiovascular Disease, at the Baylor College of Medicine in Houston, Texas, and, most recently, at the University of Washington, where he holds the title of Professor of Medicine (Hematology) and Adjunct Professor of Biochemistry and Mechanical Engineering. Dr. López is also Chief Scientific Officer of Bloodworks Northwest, a large regional blood center, and directs the Bloodworks Research Institute, where he also runs an active laboratory.
Dr. López is currently serving as Co-Director of the Translational Research Training in Hematology Program, an international program to assist in fellow-to-faculty transition cosponsored by the European Hematology Association and the American Society of Hematology.
Prof. Dominick J. Angiolillo, MD, PhD. is a Distinguished Professor of Medicine with Tenure status, Chief of Cardiology and Medical Director of the University of Florida Health Cardiovascular Center. He is also the Medical Director of Cardiovascular Research, Program Director of the ACGME-accredited Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Much of Prof. Angiolillo’s professional career has been devoted to interventional cardiology and management of patients with acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis, being a key investigator in the clinical development of numerous novel antithrombotic agents for which he has received numerous national and international academic recognitions.
Professor Clive Page, OBE, BSc, PhD, FRSB, FBPhs (Hon), FFPM (Hon) is an Emeritus Professor of Pharmacology, King’s College London. His main research interests are in the pharmacology of inflammation and respiratory disease. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company and was instrumental in the discovery and development of Ensifentrine for the treatment of COPD and other respiratory diseases which was recently approved by the FDA. Clive is a recent past President of the British Pharmacological Society and was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Royal Society of Biology President’s Medal in 2012 for “Outstanding Contributions to the Life Sciences”.
Summary
This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding feld. It serves as an
authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine,
cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and
cellular mechanisms involving platelets.
